ICPT Stock Overview
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada.
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 4/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Intercept Pharmaceuticals, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$19.00 |
| 52 Week High | US$21.86 |
| 52 Week Low | US$8.82 |
| Beta | 0.88 |
| 1 Month Change | 1.99% |
| 3 Month Change | 81.30% |
| 1 Year Change | 19.12% |
| 3 Year Change | -50.68% |
| 5 Year Change | -81.17% |
| Change since IPO | -2.06% |
Recent News & Updates
Recent updates
Revenues Working Against Intercept Pharmaceuticals, Inc.'s (NASDAQ:ICPT) Share Price Following 25% Dive
Jun 08
Intercept Pharmaceuticals (NASDAQ:ICPT) Has Debt But No Earnings; Should You Worry?
Apr 11Health Check: How Prudently Does Intercept Pharmaceuticals (NASDAQ:ICPT) Use Debt?
Dec 20Intercept touts Ocaliva benefit in transplant-free survival in liver disease type
Sep 20Intercept cuts debt further with deal to exchange convertible notes
Sep 02Intercept reduces debt with repurchases of $327.9M convertible notes
Aug 19Intercept Pharmaceuticals: Too Risky To Buy At This Stage
Aug 13Intercept Pharma Q2 2022 Earnings Preview
Aug 02Intercept to resubmit for FDA approval of NASH candidate after new analysis
Jul 07Intercept: Increase Of Ocaliva Sales And A Few Catalysts
May 23Need To Know: Analysts Are Much More Bullish On Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT)
May 10Intercept: Opportunity To Buy On Potential NDA Resubmission Of Ocaliva For NASH
Mar 05Intercept names Andrew Saik as chief financial officer
Jun 07Intercept Pharmaceuticals slides as FDA restricts Ocaliva use
May 26Intercept Pharmaceuticals, Inc. (NASDAQ:ICPT): Are Analysts Optimistic?
May 11Shareholder Returns
| ICPT | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.1% | 0.4% | 1.0% |
| 1Y | 19.1% | 0.9% | 21.9% |
Return vs Industry: ICPT exceeded the US Biotechs industry which returned -4.2% over the past year.
Return vs Market: ICPT exceeded the US Market which returned 14.1% over the past year.
Price Volatility
| ICPT volatility | |
|---|---|
| ICPT Average Weekly Movement | 22.8% |
| Biotechs Industry Average Movement | 11.6% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.8% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: ICPT's share price has been volatile over the past 3 months.
Volatility Over Time: ICPT's weekly volatility has increased from 15% to 23% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | 341 | Jerry Durso | www.interceptpharma.com |
Intercept Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics to treat progressive non-viral liver diseases in the United States, Europe, and Canada. The company markets Ocaliva, a farnesoid X receptor agonist used for the treatment of primary biliary cholangitis in combination with ursodeoxycholic acid in adults. It is also developing Ocaliva for various indications, including nonalcoholic steatohepatitis and NASH; and other product candidates in various stages of clinical and preclinical development.
Intercept Pharmaceuticals, Inc. Fundamentals Summary
| ICPT fundamental statistics | |
|---|---|
| Market cap | US$794.69m |
| Earnings (TTM) | -US$57.47m |
| Revenue (TTM) | US$317.68m |
2.5x
P/S Ratio-13.8x
P/E RatioIs ICPT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ICPT income statement (TTM) | |
|---|---|
| Revenue | US$317.68m |
| Cost of Revenue | US$632.00k |
| Gross Profit | US$317.05m |
| Other Expenses | US$374.52m |
| Earnings | -US$57.47m |
Last Reported Earnings
Sep 30, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.37 |
| Gross Margin | 99.80% |
| Net Profit Margin | -18.09% |
| Debt/Equity Ratio | 311.6% |
How did ICPT perform over the long term?
See historical performance and comparison